Previous Close | 34.90 |
Open | 34.54 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 34.52 - 34.71 |
52 Week Range | 34.52 - 34.71 |
Volume | |
Avg. Volume | N/A |
Net Assets | N/A |
NAV | N/A |
PE Ratio (TTM) | N/A |
Yield | N/A |
YTD Daily Total Return | N/A |
Beta (5Y Monthly) | N/A |
Expense Ratio (net) | N/A |
Inception Date | N/A |
PARIS, April 08, 2022--Regulatory News: Ipsen:
PARIS, March 25, 2022--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) have recommended approval of Cabometyx as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.